Revenue growth with one off cost pressures impacting profit
BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
18 August 2025
Revenue growth with one off cost pressures impacting profitability
BLIS Technologies Limited (BLIS) delivers revenue of $3.5m for the first quarter ending 30 June
2025 (1Q26), an increase of $0.1m on the same period last year. 1Q26 EBITDA is a $0.2m loss
compared to a $0.5m profit for 1Q25.
1Q26 results are characterised by growth in Private Label revenues and strong New Zealand
wholesale revenues leading into winter. Total ingredient revenues were down compared to the
same period last year, impacted by the timing of orders for one of our larger customers, but will
rebound this quarter.
1Q26 earnings have been impacted by one-off cost increases within the supply chain. The one-
off cost increase is forecast to be $0.9m in the full year FY26 with $0.7m impacting the Q1
result. Q1 EBITDA is a $0.5m profit on an underlying basis excluding one-off costs (Q1 2025
$0.5m).
“Based on current market indicators, we are forecasting revenue in 1HY26 will be around
$7.5m, driven by a strengthening of ingredient revenues. This represents an increase of 25%
from 1HY25. EBITDA (inclusive of one-off costs) for 1HY26 is expected to be a profit slightly
below the same period last year (1HY25 $0.3m).
“The timing of ingredient sales and the one-off costs in the supply chain have impacted the Q1
result. An improved Q2 result will offset the lower Q1 trading result. At this stage we are
forecasting revenue growth of between 10% and 15% for the full year FY26” said Scott
Johnson, CEO.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About BLIS Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at
www.blis.co.nz.
BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- CVT — Comvita Limited: Comvita Scheme Booklet and Notice of Meeting2025-10-14
“53 § BLIS is a small NZX listed company that develops and sells healthcare products based on strains of bacteria. The company offers BLIS K12 (an oral probiotic supplement to support ear, nose and throat health as well as for enhancing immunity and bad breath), BLIS M18 (…”
- BGP — Briscoe Group Limited: Half Year Results to 27 July 20252025-09-09
“Results announcement Results for announcement to the market Name of issuer BRISCOE GROUP LIMITED Reporting Period Half-Year – 27 January 2025 to 27 July 2025 Previous Reporting Period Half-Year – 29 January 2024 to 28 July 2024 Currency New Zealand Dollars Amoun…”
- NZK — New Zealand King Salmon Investments Limited: NZK 1HY25 (SEPT) Half Year Results2025-09-24
“25 September 2025 NZK - NEW ZEALAND KING SALMON INVESTMENTS LIMITED ANNOUNCES 1HY25 (SEPT) RESULT New Zealand King Salmon Investments Ltd (NZX & ASX: NZK) reports its financial performance for the six-month period ended 31 July 2025 (1HY25 (Sept)). Key points include:…”